Dossier assessment
Brolucizumab (neovascular age-related macular degeneration) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Brolucizumab (neovascular age-related macular degeneration) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Brolucizumab (neovascular age-related macular degeneration) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with neovascular (wet) age-related macular degeneration
Added benefit not proven due to lack of suitable study data
Project details
- Project no.
- A20-23
- Commission
- Commission awarded on 10.03.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Brolucizumab (visual impairment due to diabetic macular oedema) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed